Quick Answer
ENANTA PHARMACEUTICALS INC reported Operating Income of -$85.35 million for fiscal year 2025.
ENANTA PHARMACEUTICALS INC Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$85.35M | +29.9% |
| 2024 | -$121.69M | +11.3% |
| 2023 | -$137.21M | -10.8% |
| 2022 | -$123.84M | -13.0% |
| 2021 | -$109.57M | -163.1% |
| 2020 | -$41.64M | -213.3% |
| 2019 | $36.74M | -58.4% |
| 2018 | $88.33M | +258.9% |
| 2017 | $24.61M | -20.2% |
| 2016 | $30.84M | -75.2% |
| 2015 | $124.15M | +553.9% |
| 2014 | $18.98M | +110.3% |
| 2013 | $9.03M | -57.6% |
| 2012 | $21.29M | -15.9% |
| 2011 | $25.30M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$11.25M | +52.2% | +40.4% |
| June 30, 2025 | -$18.89M | +21.9% | +23.0% |
| March 31, 2025 | -$24.53M | +25.1% | -4.2% |
| December 31, 2024 | -$23.54M | +32.5% | +2.7% |
| June 30, 2024 | -$24.18M | +34.1% | +26.2% |
| March 31, 2024 | -$32.77M | +16.9% | +6.1% |
| December 31, 2023 | -$34.89M | -16.2% | +5.0% |
| June 30, 2023 | -$36.71M | -12.8% | +6.9% |
- ENANTA PHARMACEUTICALS INC showed an increase of +29.9% in Operating Income compared to the prior fiscal year.
- Over the 2011–2025 period, ENANTA PHARMACEUTICALS INC’s operating income has declined by 437.4% (from $25.30 million to -$85.35 million).
- The most recent figure is from ENANTA PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on November 19, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: